首页> Cancer research> Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

导出 OA

翻译打印收藏纠错

第一作者： Catherine A,Eberlein

第一单位： AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.

作者： Catherine A,Eberlein ^[1] ; Daniel,Stetson ^[2] ; Aleksandra A,Markovets ^[2] ; Katherine J,Al-Kadhimi ^[1] ; Zhongwu,Lai ^[2] ; Paul R,Fisher ^[3] ; Catherine B,Meador ^[4] ; Paula,Spitzler ^[4] ; Eiki,Ichihara ^[4] ; Sarah J,Ross ^[1] ; Miika J,Ahdesmaki ^[1] ; Ambar,Ahmed ^[2] ; Laura E,Ratcliffe ^[3] ; Elizabeth L Christey,O'Brien ^[3] ; Claire H,Barnes ^[1] ; Henry,Brown ^[1] ; Paul D,Smith ^[1] ; Jonathan R,Dry ^[2] ; Garry,Beran ^[1] ; Kenneth S,Thress ^[2] ; Brian,Dougherty ^[2] ; William,Pao ^[4] ; Darren A E,Cross ^[5]

作者单位： AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom. ^[1] AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts. ^[2] AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom. ^[3] Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. ^[4] AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom. Darren.Cross@astrazeneca.com. ^[5]